NCT01262820View on ClinicalTrials.gov

Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

September 30, 2014

Study Completion Date

October 31, 2014

Conditions
Lung Cancer
Interventions
DRUG

Pazopanib

Pazopanib, 800 mg by mouth daily each 21 day cycle

Trial Locations (2)

15232

University of Pittsburgh Medical Center, Pittsburgh

27599

North Carolina Cancer Hospital at U of North Carolina at CH, Chapel Hill

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT01262820 - Pazopanib In Stage IIIB/IV NSCLC Lung Cancer After Progression on First Line Therapy Containing Bevacizumab | Biotech Hunter | Biotech Hunter